ECM targeted IL-2 Engineering Service
Creative Biolabs provides expert, custom ECM Targeted IL-2 engineering to address the fundamental safety and efficacy limitations of systemic IL-2 research molecules. We combine proprietary ECM-binding domains (EBDs) with selective IL-2 mutein technology to anchor the drug directly within the tumor microenvironment (TME). What we provide is a robust, end-to-end preclinical pipeline service, from initial in silico design and high-affinity validation to GLP-grade protein production and in vivo PK/PD proof-of-concept.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Introduction of ECM Targeted IL-2 Engineering
IL-2 is a potent T cell growth factor whose systemic use is hindered by severe toxicity and the unwanted expansion of immunosuppressive Tregs. Engineering strategies now focus on restricting IL-2 activity spatially or mechanistically. Our solution targets the extracellular matrix (ECM), a highly enriched, non-internalizing tumor stroma component create a localized cytokine depot. This strategy, validated by successful preclinical fusion proteins targeting ECM components, fundamentally improves the safety/efficacy window by sustaining high local drug concentrations while maintaining a minimal, safe systemic exposure.
To conduct a rigorous evaluation of the proposed IL-2 mutein and its target specificity, request a consultation.
Fig.1 Interplay of IL-2/IL-2R signaling in the tumor microenvironment. 1
What We Can Offer
Custom EBD-IL2 Fusion Design
Tailored construction of your existing IL-2 mutein or a de novo design fused with high-affinity, proprietary extracellular matrix binding domains, specific to your chosen tumor ECM target (e.g., Tenascin-C splice variants or specific fibronectin isoforms).
Selective Mutein Optimization
Customized engineering protocols to ensure your final immunocytokine preferentially activates effector T cells and NK cells while actively minimizing off-target binding to immunosuppressive regulatory T cells (Tregs).
Validated Linker Stability Analysis
Comprehensive in silico and in vitro assessment of the linker stability, specifically designed to resist premature cleavage by the high concentration of proteases in the tumor microenvironment.
High-Resolution Affinity Measurement
Quantitative surface plasmon resonance (SPR) analysis to guarantee the desired picomolar affinity necessary for sustained, localized drug retention and superior tumor-to-blood ratios.
ECM targeted IL-2 Engineering Service at Creative Biolabs
Why Choose Us?
|
Key Advantages
|
Unique Features
|
|
Proprietary EBD Library
|
Access to a diverse, proprietary library of high-affinity EBDs tailored for specific tumor ECM components, ensuring optimal binding kinetics and localization.
|
|
Safety-First Design
|
Our dual strategy of combining EBD-mediated localization with Treg-selective IL-2 muteins ensures both physical (spatial) and biological (receptor) selectivity.
|
|
Validated Strategy
|
We utilize targeting principles confirmed by Published Data demonstrating the potent anti-cancer activity of non-internalizing fusion proteins targeting the tumor stroma.
|
Contact us to review the requirements for your specific construct.
Customer Reviews
-
Sustained Local Activity
The utilization of Creative Biolabs' ECM targeted IL-2 engineering service has demonstrably facilitated sustained anti-tumor activity within TME models, consequently necessitating less frequent administration. - R. M***a.
-
Enhanced Selectivity
Implementation of Creative Biolabs' ECM targeted IL-2 engineering service has substantially improved IL-2 mutein specificity, successfully minimizing Treg activation while concurrently maximizing CD8+ proliferation. - S. J***s.
FAQs
Q: Why is ECM targeting superior to just using a Treg-selective IL-2 mutein alone?
A: Treg-selective muteins solve the biological challenge of Treg activation, but they often still suffer from rapid systemic clearance and require frequent dosing. Our ECM targeting provides a physical localization layer, achieving both Treg avoidance and prolonged local retention. This dual strategy maximizes the research index far beyond what receptor selectivity alone can achieve.
Q: Can Creative Biolabs apply this service to my existing IL-2 mutein, or do I need to use yours?
A: Absolutely, our service is modular. We can integrate our proprietary EBDs and optimized linkers onto your existing IL-2 mutein sequence. Our engineers will perform a structural assessment to ensure compatibility and stability in the proteolytic TME before moving to synthesis.
Related Services
Antibody-Drug Conjugate (ADC) Development
Leverage our expertise in EBD technology for the localized delivery of cytotoxic payloads or small molecule drugs, using the same non-internalizing targeting validated by our IL-2 platform.
Learn More →
Antibody and Protein Production
For clients preparing for advanced preclinical testing, we offer scale-up, manufacturing, and fill-finish services for your final IL-2 fusion protein candidate, adhering to strict regulatory standards.
Learn More →
How to Contact Us
Creative Biolabs provides a validated, end-to-end solution that addresses the systemic toxicity of IL-2 while harnessing its full immune activation potential, enabling robust combination strategies and durable responses in preclinical models. To discuss your project requirements, review our proprietary EBD data, and initiate your lead optimization program, please contact us.
Reference
-
Muhammad, Shan et al. "Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies." Molecular cancer vol. 22,1 121. 29 Jul. 2023. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12943-023-01826-7
For Research Use Only | Not For Clinical Use
